Canine Lymphoma: Treatment Options, Costs, and Clinical Trials in 2026
By Brycen Levings | Editor: Tariq Shah · May 29, 2026
What Is Canine Lymphoma?
Lymphoma is a cancer of the lymphatic system — the network of nodes and vessels that plays a central role in immune function. In dogs, it can appear in several distinct forms depending on which cell type is involved and where in the body it originates. Multicentric Lymphoma The most common presentation involves simultaneous enlargement of multiple peripheral lymph node regions throughout the body. Most cases are B-cell in origin. Pet Trial Finder currently tracks 7 active trials specifically targeting multicentric lymphoma. B-Cell Lymphoma B-cell lymphoma arises from malignant B lymphocytes and typically involves lymph nodes, spleen, and bone marrow. It generally carries a more favorable prognosis than T-cell lymphoma when treated with combination chemotherapy. There are 12 active B-cell lymphoma trials in our database. T-Cell Lymphoma T-cell lymphoma tends to carry a more guarded prognosis and is often more resistant to standard chemotherapy protocols. It can present in multicentric, alimentary, and cutaneous variants. Pet Trial Finder tracks 7 active T-cell lymphoma trials. Cutaneous Epitheliotropic Lymphoma (Mycosis Fungoides) A rare but aggressive form that primarily affects the skin, typically presenting as scaling, redness, or ulceration. It is challenging to diagnose and historically difficult to treat. There are 7 active trials exploring new protocols for this subtype.
Standard Treatment and What It Costs
The standard of care for canine lymphoma is multi-agent chemotherapy. The CHOP protocol — named for its four drugs cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone — is the most widely used and has the best documented response rates. CHOP protocol (19-week course): $5,000 to $10,000 depending on the institution and the dog's weight Single-agent doxorubicin (less intensive): $3,000 to $5,000 Prednisone alone (palliative, minimal life extension): $50 to $150/month Specialist oncology consultations: $200 to $500 per visit Response rates with CHOP are generally good — 60 to 90% of dogs with B-cell lymphoma achieve remission. Median remission duration is 9 to 12 months, with some dogs living 2 or more years with treatment. T-cell lymphoma responds less predictably, with shorter median remissions. The limitation of standard chemotherapy is its ceiling. Once lymphoma relapses, rescue protocols become less effective and more expensive. This is where clinical trials are making a meaningful difference.
Clinical Trials for Canine Lymphoma: What Is Being Studied
Pet Trial Finder currently has 19 active lymphoma trials across 24 institutions. These are not experimental in the alarming sense — they are rigorously designed, IRB-approved studies conducted by board-certified veterinary oncologists at accredited teaching hospitals. The areas of active investigation include the following: CAR-T Cell Therapy Chimeric antigen receptor T-cell therapy involves engineering a dog's own immune cells to recognize and attack lymphoma cells. This approach has shown dramatic results in human lymphoma patients and is now being evaluated in dogs, whose lymphoma biology closely mirrors the human disease. Checkpoint Inhibitors These drugs — sometimes called immunotherapy — block signals that cancer cells use to hide from the immune system. Several trials are investigating checkpoint inhibitors alone and in combination with CHOP for both B-cell and T-cell lymphoma. Oral Kinase Inhibitors Targeted small molecule drugs that disrupt specific signaling pathways driving lymphoma cell growth. Some are available daily oral medications that can be administered at home, reducing the frequency of required clinic visits. Novel Combination Protocols Several trials are testing modified CHOP-based protocols with added agents designed to extend remission duration or overcome drug resistance in relapsed cases.
Who Qualifies for a Lymphoma Trial?
Each trial has specific eligibility criteria, but most lymphoma trials are looking for dogs with a confirmed diagnosis via biopsy or cytology, adequate organ function (bloodwork will be evaluated at the screening visit), and a clearly established subtype (B-cell vs T-cell, as many trials are subtype-specific). Some trials specifically want treatment-naive patients — meaning dogs who have not yet received chemotherapy. Others are designed for dogs who have relapsed after standard treatment and need a rescue option. Both types are represented in our current database.
How Trial Costs Compare to Standard Treatment
Fully funded lymphoma trials cover the investigational drug, all required imaging and diagnostics specific to the trial protocol, and specialist monitoring appointments. This can represent a significant saving compared to the $5,000 to $10,000 cost of standard CHOP. Partially funded trials cover the novel agent and key diagnostics, with some standard care components potentially applying. The honest comparison: if your dog qualifies for a fully funded CAR-T trial, the novel therapy is provided at no cost while your dog receives an extraordinary level of specialist attention. The tradeoff is more frequent visits to the research institution and a willingness to accept the uncertainty that comes with investigational treatment. Pet Trial Finder checks your dog against all 19 active lymphoma trials — plus the full database of 133 trials across 39 cancer types — in a single application. Results in hours, not weeks.